Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Stock Down 0.2 %

Marinus Pharmaceuticals stock opened at $0.55 on Wednesday. The business has a 50-day simple moving average of $0.55 and a 200 day simple moving average of $0.72. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $9.07. The stock has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. World Investment Advisors LLC purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth approximately $104,000. Virtu Financial LLC purchased a new position in Marinus Pharmaceuticals in the fourth quarter worth $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Marinus Pharmaceuticals in the fourth quarter valued at $54,000. JPMorgan Chase & Co. raised its position in Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares in the last quarter. Finally, Deltec Asset Management LLC bought a new stake in Marinus Pharmaceuticals during the fourth quarter worth about $107,000. 98.80% of the stock is currently owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.